Interview with Aristides Torres Velasco, CEO, Vanquish Mexico
Can you give us a brief history of the company since your merger in 2003: the main growth drivers, opportunities and challenges? Laboratorios Vanquish was born in 2003, before that…
Address: Blvd, Adolfo Ruiz Cortines No. 4249, Piso 2 Col. Jardines de la Montana C.P. 14210, Mexico
Tel: 01 800 6334 4505
Web: http://www.vanquish.com.mx/
Laboratorios Vanquish was started in 2003 and as a young company has successfully patented one active molecule for Mexico, the United States, and Europe, while also manufacturing and developing generics in the fields of CNS, cardiovascular, oncology and gynaecology. With a strong portfolio in both the public and private market in Mexico, Vanquish is moving forward and now exporting selected products to the United States, and also has manufacturing operations with a partner company in Brazil.
CNS, cardiovascular, oncology, gynaecology, and dietary supplements
Can you give us a brief history of the company since your merger in 2003: the main growth drivers, opportunities and challenges? Laboratorios Vanquish was born in 2003, before that…
Alejandro Luna and José Alfredo Sedano, lawyers at the leading legal firm of Santamarina y Steta, discuss the current legal challenges faced by companies in the pharmaceutical and healthcare sector…
The general manager in charge of Mexico, Central America and the Caribbean is on board with the corporate mission of doubling Shire’s product sales to USD 10 billion by 2020…
In the Mexican pharmaceutical industry change is the name of the game. The general director of Pierre Fabre Mexico and Central America expands on how the company has adapted its…
The general director of the National Institute for Psychiatry discusses the Institute’s commitment to translating clinical research into better care for patients, the social stigma patients with mental disorders still…
Johannes Hauser, managing director of the German-Mexican Chamber of Commerce explains the role of the chamber in Mexico and encourages small and medium-sized companies in Germany to consider the country…
Oscar Parra, general manager at Lundbeck Mexico, explains the seriousness of CNS diseases in increasingly urbanized countries and the impact they can have on the productivity of the Mexican workforce.…
The first woman appointed as general director of one of the leading neurosciences institutions in Latin America discusses the Institute’s priorities in terms of R&D for brain diseases, training of…
Probiomed wants to move to the next level. The recently appointed general director discusses her plans to grow the business and expand internationally, leveraging the company’s in-house developed biotech products…
Genomic medicine is gaining momentum. The general director of the institute founded in 2004 explains how genomics is helping unlocking the secret codes, which will help understand and treat pathologies…
For 40 years Apotex has made providing patients around the globe with access to quality and affordable medicines its priority. The general director for Northern Latin America discusses the importance…
Rodrigo Iturralde, general manager of Randall, walks us through the new plans of the company after a year of difficult yet enriching challenges and the ambitious goals set with an…
Healthcare coverage has gone a long way in Mexico after the implementation of the Seguro Popular in 2004 and today 57.3 million Mexicans are affiliated to the public health insurance…
See our Cookie Privacy Policy Here
